7.21Open7.21Pre Close0 Volume6 Open Interest10.00Strike Price0.00Turnover238.97%IV-12.51%PremiumJan 17, 2025Expiry Date9.67Intrinsic Value100Multiplier11DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9682Delta0.0088Gamma2.01Leverage Ratio-0.0268Theta0.0027Rho1.94Eff Leverage0.0024Vega
Grail Stock Discussion
Larger Image: tradingview.com...
$Grail (GRAL.US)$
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL (NASDAQ: GRAL) has announced significant progress in its clinical trials for the Galleri® multi-cancer early detection (MCED) test. The company has completed enrollment of over 35,000 participants in the PATHFINDER 2 study across North America and finished the final study visits for the NHS-Galleri trial with more than 140,000 participants in England. Results from the first 25,000 PATHFINDER 2 participan...
No comment yet